These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 18596603

  • 1. Chemoprevention in postmenopausal women.
    Rastogi P.
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [Abstract] [Full Text] [Related]

  • 2. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA, Land SR.
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [Abstract] [Full Text] [Related]

  • 3. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB.
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [Abstract] [Full Text] [Related]

  • 4. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [Abstract] [Full Text] [Related]

  • 5. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG.
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.
    J Natl Cancer Inst; 2006 Jan 18; 98(2):110-5. PubMed ID: 16418513
    [Abstract] [Full Text] [Related]

  • 9. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.
    J Natl Cancer Inst; 2005 Nov 16; 97(22):1652-62. PubMed ID: 16288118
    [Abstract] [Full Text] [Related]

  • 10. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.
    Clin Cancer Res; 2006 Sep 01; 12(17):5242-7. PubMed ID: 16951244
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett SA, Agnusdei D, Stuenkel CA.
    Menopause; 2009 Sep 01; 16(2):413-21. PubMed ID: 19092711
    [Abstract] [Full Text] [Related]

  • 15. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM.
    Clin Cancer Res; 2003 Jan 01; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [Abstract] [Full Text] [Related]

  • 16. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF, Chlebowski RT.
    Menopause; 2008 Jan 01; 15(4 Suppl):804-9. PubMed ID: 18596602
    [Abstract] [Full Text] [Related]

  • 17. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
    Olevsky OM, Martino S.
    Menopause; 2008 Jan 01; 15(4 Suppl):790-6. PubMed ID: 18596600
    [Abstract] [Full Text] [Related]

  • 18. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK, Ford LG.
    Eur J Cancer Prev; 2007 Jun 01; 16(3):232-42. PubMed ID: 17415094
    [Abstract] [Full Text] [Related]

  • 19. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
    Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators.
    N Engl J Med; 2006 Jul 13; 355(2):125-37. PubMed ID: 16837676
    [Abstract] [Full Text] [Related]

  • 20. The Breast Cancer Continuum: insights from the tamoxifen trials impact future drug development strategies.
    Lewis JP.
    Ann N Y Acad Sci; 2001 Dec 13; 949():327-32. PubMed ID: 11795371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.